Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
J Am Soc Nephrol
; 30(12): 2449-2463, 2019 12.
Article
in En
| MEDLINE
| ID: mdl-31575699
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Complement Inactivating Agents
/
Antibodies, Monoclonal, Humanized
/
Atypical Hemolytic Uremic Syndrome
Type of study:
Observational_studies
/
Prognostic_studies
/
Screening_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
J Am Soc Nephrol
Journal subject:
NEFROLOGIA
Year:
2019
Type:
Article